J&J-MERCK's U.K. LAUNCH OF OTC FAMOTIDINE (PEPCID AC)
This article was originally published in The Tan Sheet
J&J-MERCK's U.K. LAUNCH OF OTC FAMOTIDINE (PEPCID AC) began the week of Feb. 14 under the aegis of the joint venture's new Centra Healthcare subsidiary. The consumer launch of the product closely follows the U.K. Medicines Control Agency's Jan. 21 decision to allow the switch from prescription-only status to pharmacy availability of famotidine and 10 other drugs -- including cimetidine (SmithKline Beecham's Tagamet) and beclomethasone dipropionate (Glaxo/Warner-Lambert's Beconase).
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC